Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0HF0A
|
||||
| Former ID |
DIB019779
|
||||
| Drug Name |
DQP-1105
|
||||
| Synonyms |
KB-272091
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [531589] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C29H24BrN3O4
|
||||
| InChI |
InChI=1S/C29H24BrN3O4/c1-17-7-12-22-21(15-17)27(19-5-3-2-4-6-19)28(29(37)31-22)23-16-24(18-8-10-20(30)11-9-18)33(32-23)25(34)13-14-26(35)36/h2-12,15,24,28H,13-14,16H2,1H3,(H,35,36)
|
||||
| InChIKey |
ACUGSRUCGXYFTL-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Glutamate [NMDA] receptor subunit epsilon 2 | Target Info | Modulator (allosteric modulator) | [531589] | |
| GluN2C | Target Info | Modulator (allosteric modulator) | [531589] | ||
| GluN2D | Target Info | Modulator (allosteric modulator) | [531589] | ||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Circadian entrainment | |||||
| Long-term potentiation | |||||
| Glutamatergic synapse | |||||
| Dopaminergic synapse | |||||
| Alzheimer's disease | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Huntington's disease | |||||
| Cocaine addiction | |||||
| Amphetamine addiction | |||||
| Nicotine addiction | |||||
| Alcoholism | |||||
| Systemic lupus erythematosus | |||||
| Pathway Interaction Database | ErbB4 signaling events | ||||
| Reelin signaling pathway | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.